S&P 500 ^GSPC
5,011.12
-0.22%
Tesla TSLA
$149.83
-3.62%
Microsoft MSFT
$404.33
-1.82%
Meta META
$501.80
+1.54%
Amazon AMZN
$179.17
-1.16%
Nvidia NVDA
$846.71
+0.76%
Apple AAPL
$167.04
-0.57%
Alphabet GOOG
$157.46
+0.37%

A penny stock with growth potential

-Precision Cancer Treatment:Accuray $ARAY+0.9% specializes in the development of medical devices such as CyberKnife and Radixact that deliver precise doses of radiation to treat cancer with the utmost precision.

-International development: with more than 1,000 system installations in 60 countries, Accuray $ARAY+0.9% has consolidated its position in the field of radio-oncology.

- Expansion into new markets: The approval of the Tomo C system in China and the planned entry of the Helix system in the Indian market show the company's growing presence in emerging markets.

- Analyst support: Analyst Jason Wittes of Roth Capital expresses support for Accuray, highlights solid progress in China and India, and expects increased investor attention.

- Strong growth potential: With a consensus rating of "Strong Buy" among analysts and an average target share price of $9.67, Accuray presents the opportunity for exceptional growth of up to 287%. 📈💼

How could Accuray's new systems impact access to treatment in developing countries and what do you think of the company as a whole?

ARAY
$2.21 $0.02 +0.91%
1 Day
+0.01%
5 Days
+1.16%
1 Month
+6.07%
6 Months
-1.87%
YTD
-8.07%
1 Year
-11.49%
5 Years
-46.75%
Max.
-90.8%

No comments yet